<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000145.v2.p2" parentStudy="phs000145.v2.p2" createDate="2009-09-11" modDate="2010-06-29">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>CoLaus Co-Principle Investigator (Academia)</td><td>Peter Vollenweider</td><td>Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</td></tr>
		<tr><td>CoLaus Co-Principle Investigator (Industry)</td><td>Dawn M. Waterworth</td><td>GlaxoSmithKline, Philadelphia, Pennsylvania, USA</td></tr>
		<tr><td>LOLIPOP Co-Principle Investigators</td><td>Jaspal S. Kooner</td><td>National Heart and Lung Institute, Imperial College London, UK</td></tr>
		<tr><td>LOLIPOP Co-Principle Investigators</td><td>John C. Chambers</td><td>Department of Epidemiology and Public Health, Imperial College London, UK</td></tr>
		<tr><td>African American Controls Co-Principle Investigators</td><td>Jorge R. Oksenberg</td><td>Department of Neurology, University of California, San Francisco, CA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>POPRES: Population Reference Sample</StudyNameEntrez>
	<StudyNameReportPage>POPRES: Population Reference Sample</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Population</StudyType>
		<StudyType>Control Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Technological and scientific advances, stemming in large part from the Human Genome and HapMap projects, have made  	large-scale, genome-wide investigations feasible and cost-effective.  These advances have the potential to dramatically impact  	drug discovery and development by identifying genetic factors that contribute to variation in disease risk as well as drug  	pharmacokinetics, treatment efficacy, and adverse drug reactions.  In spite of the technological advancements, successful application  	in biomedical research would be limited without access to suitable sample collections.  To facilitate exploratory genetic research,  	we have assembled a DNA resource from a large number of subjects participating in multiple studies throughout the world.  This resource  	was initially genotyped using the Affymetrix 500K SNP panel.  This project includes nearly 6,000 subjects of African American, East  	Asian, South Asian, Mexican, and European origin.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>The POPRES collection includes subjects from ten individual collections.  These collections are a mix of unrelated population samples and  		healthy controls, and are described in Nelson et al. (PMID:   		<a href="http://www.ncbi.nlm.nih.gov/pubmed/18760391" target="_blank">18760391</a>).</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="18760391"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18262040"/>
		</Publication>
		<Publication>
			<Pubmed pmid="18193046"/>
		</Publication>
		<Publication>
			<Pubmed pmid="14669136"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Normalcy"/>
	</Diseases>
	<Attributions>
		<Header title="POPRES Team Leader">
			<AttName>Matthew R. Nelson</AttName>
			<Institution>GlaxoSmithKline, Research Triangle Park, NC, USA</Institution>
		</Header>
		<Header title="CoLaus Principle Investigator (Academia)">
			<AttName>G&#233;rard Waeber</AttName>
			<Institution>Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</Institution>
		</Header>
		<Header title="CoLaus Principle Investigator (Industry)">
			<AttName>Vincent Mooser</AttName>
			<Institution>GlaxoSmithKline, Philadelphia, Pennsylvania, USA</Institution>
		</Header>
		<Header title="CoLaus Co-Principle Investigator (Academia)">
			<AttName>Peter Vollenweider</AttName>
			<Institution>Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</Institution>
		</Header>
		<Header title="CoLaus Co-Principle Investigator (Industry)">
			<AttName>Dawn M. Waterworth</AttName>
			<Institution>GlaxoSmithKline, Philadelphia, Pennsylvania, USA</Institution>
		</Header>
		<Header title="LOLIPOP Co-Principle Investigators">
			<AttName>Jaspal S. Kooner</AttName>
			<Institution>National Heart and Lung Institute, Imperial College London, UK</Institution>
		</Header>
		<Header title="LOLIPOP Co-Principle Investigators">
			<AttName>John C. Chambers</AttName>
			<Institution>Department of Epidemiology and Public Health, Imperial College London, UK</Institution>
		</Header>
		<Header title="African American Controls Co-Principle Investigators">
			<AttName>Jorge R. Oksenberg</AttName>
			<Institution>Department of Neurology, University of California, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="African American Controls Co-Principle Investigators">
			<AttName>Stephen L. Hauser</AttName>
			<Institution>Department of Neurology, University of California, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="Duke Controls Principle Investigator">
			<AttName>David B. Goldstein</AttName>
			<Institution>Center for Population Genomics and Pharmacogenetics, Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA</Institution>
		</Header>
		<Header title="Duke Controls Co-Investigator">
			<AttName>Anna C. Need</AttName>
			<Institution>Center for Population Genomics and Pharmacogenetics, Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="0" shortName="NRUP" longName="Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects."/>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHGRI</DacName>
      <DacFullName>National Human Genome Research Institute</DacFullName>
      <DacEmail>nhgridac@mail.nih.gov</DacEmail>
      <DacPhone></DacPhone>
      <DacFax>301-480-2770</DacFax>
      <DacUrl>http://grants.nih.gov/grants/gwas</DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000145.v2.p2_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
               The Requester agrees to acknowledge the NIH GWAS Data Repository and properly cite the primary publication arising from the POPRES initiative in all oral and written presentations, disclosures, and publications resulting from any analyses of the data. The Requester further agrees that the acknowledgment shall include the dbGaP accession number to the specific version of the dataset(s) analyzed. The primary POPRES citation is: Nelson MR, Bryc K, King KS, Indap I, Boyko AR, Novembre J, Briley L, Maruyama Y, Waterworth DM, Waeber G, Vollenweider P, Oksenberg JR, Hauser SL, Stirnadel HA, Kooner JS, Chambers JC, Jones B, Mooser V, Bustamante CD, Roses AD, Burns DK, Ehm MG, and Lai EH (2008). The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research. Am. J. Hum. Genet., 83:347-358 28 August 2008.
               A sample statement for the acknowledgment of the POPRES dataset(s) follows: The collections and methods for the Population Reference Sample (POPRES) are described by Nelson et al. (2008). The datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000145.v1.p1 through dbGaP accession number phs000145.v1.p1.
            </para>
        <para>
               The Requester agrees to acknowledge the NIH GWAS Data Repository and properly cite the primary publication arising from the POPRES initiative in all oral and written presentations, disclosures, and publications resulting from any analyses of the data. The Requester further agrees that the acknowledgment shall include the dbGaP accession number to the specific version of the dataset(s) analyzed. The primary POPRES citation is: Nelson MR, Bryc K, King KS, Indap I, Boyko AR, Novembre J, Briley L, Maruyama Y, Waterworth DM, Waeber G, Vollenweider P, Oksenberg JR, Hauser SL, Stirnadel HA, Kooner JS, Chambers JC, Jones B, Mooser V, Bustamante CD, Roses AD, Burns DK, Ehm MG, and Lai EH (2008). The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research. Am. J. Hum. Genet., 83:347-358 28 August 2008.
               A sample statement for the acknowledgment of the POPRES dataset(s) follows: The collections and methods for the Population Reference Sample (POPRES) are described by Nelson et al. (2008). The datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000145.v1.p1 through dbGaP accession number phs000145.v1.p1.
            </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certification" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000145.v2.p2" FileName="GSK-POPRES_DUC_082908.final.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>The Population Reference Sample (POPRES) study allows use of these data by investigators employed by non-profit and for-profit organizations.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
